Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001916217 | SCV002178858 | uncertain significance | not provided | 2024-09-29 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 1968 of the VCAN protein (p.Gln1968Glu). This variant is present in population databases (rs775630677, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with VCAN-related conditions. ClinVar contains an entry for this variant (Variation ID: 1410017). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The glutamic acid amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV003416584 | SCV004108851 | uncertain significance | VCAN-related disorder | 2023-08-31 | criteria provided, single submitter | clinical testing | The VCAN c.5902C>G variant is predicted to result in the amino acid substitution p.Gln1968Glu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.014% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/5-82834724-C-G). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ce |
RCV001916217 | SCV004159062 | likely benign | not provided | 2023-02-01 | criteria provided, single submitter | clinical testing | VCAN: BP4, BS2 |